(45) reported in their study that four (44%) of nine OCS patients expressed VEGF, a biomarker associated with poorer prognosis in various cancers, and antiangiogenic agents like bevacizumab could be considered potentially useful (46, 47). The gene discussed is VEGFA; the disease is cancer.